Peter Diamandis

Diamandis has publicly endorsed a concrete, prevention- and optimization-centered longevity vision through Fountain Life, focused on AI, scans, biomarkers, early disease detection, and personalized interventions to extend healthspan. He also publicly endorsed GDF11-based rejuvenation work via Elevian, suggesting interest in biological restoration. However, the evidence lacks direct destination-style statements, timelines, or a clearly articulated durable vision for ending aging or radically extending lifespan, so the score is moderate rather than high.

Citation metrics are the primary signal and show limited scientific influence: h-index 7, 287 total citations, and no heavily cited field-shaping scientific papers. The most-cited item is a popular technology book, while the longevity-relevant paper has only 29 citations. Evidence supports some direct scientific participation, but not substantial or agenda-setting impact.

The provided evidence contains no credible disclosed investments, donations, fund allocations, or longevity-focused institution-building capital attributable to Peter Diamandis. The dimension applies, but the evidence packet supports no capital deployment score.

Strategic taste applies because Diamandis has founded or co-founded longevity-relevant organizations, but the provided evidence does not document a clear thesis, timing, contrarian insight, stage preference, risk appetite, counterfactual importance, or field-opening rationale. The evidence supports some organization-building activity in longevity-adjacent areas, but not enough to credit strong strategic judgment under this rubric.

Field creation applies: the evidence says Diamandis founded or co-founded three longevity-relevant companies, which is a meaningful organization-building signal. However, the provided primary sources mainly document a paper and citation profile, not independent corroboration of those organizations' creation or field-level effects, so the independence gate prevents a higher score.

The dimension is applicable, but the provided evidence contains no credible indication of public risk-taking, contrarian longevity advocacy, career or financial sacrifice, sustained conviction under criticism, or self-experimentation. The available sources show publication/citation activity and one aging-related AI paper, but not bravery or conviction as defined by the rubric.

Multiplier effect applies because Diamandis is credited with founding or co-founding multiple longevity-adjacent organizations, which is a concrete leverage pathway beyond direct individual work. However, the provided evidence does not document follow-on capital attracted, policy influence, talent networks, public legitimacy effects, collaborators, founder lineage, or independently corroborated downstream impact from those organizations. Primary bibliometric evidence shows modest citation reach but not field-defining leverage in longevity.